End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.21 CNY | -0.49% | -1.71% | -41.96% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.96% | 404M | - | ||
+55.70% | 59.34B | B- | ||
+41.08% | 40.24B | A | ||
-5.39% | 39.88B | B | ||
-5.56% | 28.55B | C | ||
+16.46% | 27.26B | B- | ||
-20.56% | 19.23B | B | ||
+33.03% | 12.61B | C+ | ||
+25.85% | 12.28B | B+ | ||
+2.72% | 12.49B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688073 Stock
- Ratings Bide Pharmatech Co., Ltd.